Stockreport

Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide [Seeking Alpha]

Nurix Therapeutics, Inc. - Common stock  (NRIX) 
PDF Company is set to initiate a global phase 3 confirmatory trial for bexobrutideg in mid-2026, targeting patients post-BTK therapy and benchmarking against pirtobrutinib. [Read more]